At the news
? NEUTRALIMPACT 3/10 COURT-RULING filed Aug 2, 2026 at 20:00 ET
The Delaware Court of Chancery resolved final judgment interest calculations in a post-merger indemnification dispute between Alexion (now part of AstraZeneca) and former Syntimmune shareholders. The court ordered a hybrid interest approach: AstraZeneca's subsidiary must pay prejudgment interest on the full $130M milestone payment from October 2022 to September 2024, then interest on the net balance after offsetting ~$12M in indemnification claims. The ruling finalizes a liability with net exposure of roughly $118M plus interest, but the amount is immaterial (less than 0.05% of AZN's $250B market cap), resulting in no meaningful financial or operational impact to AstraZeneca.
- The court ordered AstraZeneca's subsidiary Alexion to pay prejudgment interest on $130M milestone from Oct 2022 to Sept 2024, then interest on the balance after offsetting ~$12M in indemnification.
- AstraZeneca's total net exposure from this ruling is approximately $118M plus interest - less than 0.05% of its $249.8B market cap.
- The ruling resolves a procedural interest calculation dispute, not a new liability - the $130M milestone and $12M indemnification amounts were already determined in prior 2024-2026 rulings.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access